期刊
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
卷 52, 期 5, 页码 606-608出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/00365521.2017.1280530
关键词
Rituximab; anti-CD20 therapy; inflammatory bowel disease; Crohn's disease; lymphoma
The use of rituximab has significantly improved outcomes in patients with haematological malignancies and autoimmune disease. There are reports of rituximab-associated ulcerative colitis; however, we report for the first time, two cases of rituximab-induced Crohn's disease in elderly patients treated for lymphoma. Both patients had evidence of inflammation, ulceration, and granulomas consistent with Crohn's disease, and responded well to immunosuppression. The association of rituximab and ileocolitis suggests a protective effect of CD20+ lymphocytes in the gut, and implicates their depletion to the development and exacerbation of inflammatory bowel disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据